Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) Director Lorenzo Tallarigo sold 2,000 shares of the stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $243.06, for a total value of $486,120.00. The sale was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on ICPT. Analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, June 30th. They set an “outperform” rating and a $425.00 price target on the stock. Finally, analysts at Summer Street reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $457.56.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.77% on Wednesday, hitting $226.95. The stock had a trading volume of 442,154 shares. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock has a 50-day moving average of $254.2 and a 200-day moving average of $286.8. The company’s market cap is $4.786 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.82 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.